{"organizations": [], "uuid": "fc523121f46e6e98c17aac2f9aaa11563c3399e1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-mallinckrodt-receives-fda-acceptan/brief-mallinckrodt-receives-fda-acceptance-of-stannsoporfin-new-drug-application-filing-idUSASB0C78P", "country": "US", "domain_rank": 408, "title": "BRIEF-Mallinckrodt Receives FDA Acceptance Of Stannsoporfin New Drug Application Filing", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-23T14:02:00.000+02:00", "replies_count": 0, "uuid": "fc523121f46e6e98c17aac2f9aaa11563c3399e1"}, "author": "", "url": "https://www.reuters.com/article/brief-mallinckrodt-receives-fda-acceptan/brief-mallinckrodt-receives-fda-acceptance-of-stannsoporfin-new-drug-application-filing-idUSASB0C78P", "ord_in_thread": 0, "title": "BRIEF-Mallinckrodt Receives FDA Acceptance Of Stannsoporfin New Drug Application Filing", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "mallinckrodt plc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "mallinckrodt", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "mallinckrodt plc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 04 PM / Updated 8 minutes ago BRIEF-Mallinckrodt Receives FDA Acceptance Of Stannsoporfin New Drug Application Filing Reuters Staff Feb 23 (Reuters) - Mallinckrodt Plc: * MALLINCKRODT RECEIVES FDA ACCEPTANCE OF STANNSOPORFIN NEW DRUG APPLICATION FILING * MALLINCKRODT PLC - UNDER PRESCRIPTION DRUG USER FEE ACT, FDA HAS SET ITS ACTION DATE TO RESPOND TO STANNSOPORFIN NDA AS AUGUST 22, 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-23T14:02:00.000+02:00", "crawled": "2018-02-23T14:21:04.004+02:00", "highlightTitle": ""}